Pharmacogenomic Testing for Cardiovascular and Cerebrovascular Disease medications, by detecting and analyzing the polymorphism of 55 genes related to 67 commonly used clinical drugs for cardiovascular and cerebrovascular diseases, can guide clinical practice in choosing appropriate medications for specific patients, enabling personalized treatment. This will enhance the effectiveness and safety of medication and reduce the risk of serious adverse drug reactions.
High efficiency and accuracy
Authoritative guidance
Convenient operation
Patients taking cardiovascular and cerebrovascular drugs for the first time.
Patients taking multiple medications simultaneously or for a long time.
Patients who have an unsatisfactory response to a certain drug.
Patients who have had adverse drug reactions themselves or among their family members.
Certain groups (those with impaired liver or kidney function, the elderly, children, etc.).
People who attach importance to safe medication.
Individualized precision medicine
Provide reference for clinical rational drug use
Improve drug efficacy
Reduce adverse drug reactions
Informed consent
Sample collection
Nucleic acid extraction
Library preparation
Next generation sequencing
Data analysis
Report distribution
7 to 10 working days after receiving qualified samples.